3-(1,2,4,6,7,9a-hexahydro-2H-quinolizine-2-yl)-5-azaindole

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹嗪类
• 英文名称: 3-(1,2,4,6,7,9a-hexahydro-2H-quinolizine-2-yl)-5-azaindole
• 英文别名: 2-(1H-pyrrolo[3,2-c]pyridin-3-yl)-2,3,4,6,7,9a-hexahydro-1H-quinolizine
• 化学式: C₁₆H₁₉N₃
• 分子量: 253.347
• InChiKey: VVSGEWBCDWQFCQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  19
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  31.9
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• Azaindoles having serotonin receptor affinity
  申请人：Edwards Louise

  公开号：US20050239788A1

  公开（公告）日：2005-10-27

  Described herein are compounds with affinity for the 5-HT 6 receptor, which have the general formula I: wherein: R represents a group of Formula II or Formula III; one of A, B D or E is a N atom, the remainder being CH groups; R 1 is selected from the group consisting of SO 2 Ar, C(O)Ar, CH 2 Ar and Ar; R 2 , R 3 and R 4 are independently selected from the group consisting of H and alkyl; represents a single or double bond, with the proviso that there is only one double bond in the ring at a time; n is an integer of from 1-3; Z is selected from the group consisting of C, CH and N, provided that when is a double bond, Z is C and when is a single bond, Z is selected from CH and N; Ar is an optionally substituted aryl group; with the proviso that when R is a group of Formula II, R 1 is SO 2 Ar. Also described is the use of these compounds as pharmaceuticals to treat indications where inhibition of the 5-HT 6 receptor is implicated, such as schizophrenia.

  本文描述了具有亲和力的化合物5-HT6受体，其具有一般式I：其中：R代表式II或式III的一个基团；A、B、D或E中的一个是N原子，其余为CH基团；R1从SO2Ar、C（O）Ar、CH2Ar和Ar的组中选择；R2、R3和R4独立地从H和烷基的组中选择；表示单键或双键，但环中只有一个双键；n为1-3的整数；Z从C、CH和N的组中选择，但当为双键时，Z为C，当为单键时，Z从CH和N中选择；Ar是可选取代的芳基基团；条件是当R为式II的基团时，R1为SO2Ar。还描述了这些化合物作为药物的使用，用于治疗5-HT6受体抑制所涉及的症状，如精神分裂症。
• Azaindoles having serotonin receptor affnity
  申请人：Allelix Biopharmaceuticals, Inc.

  公开号：US20010049441A1

  公开（公告）日：2001-12-06

  Described herein are compounds with affinity for the 5-HT 6 receptor, which have the general formula I: 1 wherein: R represents a group of Formula II or Formula III; one of A, B D or E is a N atom, the remainder being CH groups; R 1 is selected from the group consisting of SO 2 Ar, C(O)Ar, CH 2 Ar and Ar; R 2 , R 3 and R 4 are independently selected from the group consisting of H and alkyl; ----- represents a single or double bond, with the proviso that there is only one double bond in the ring at a time; n is an integer of from 1-3; Z is selected from the group consisting of C, CH and N, provided that when ----- is a double bond, Z is C and when ----- is a single bond, Z is selected from CH and N; Ar is an optionally substituted aryl group; with the proviso that when R is a group of Formula II, R 1 is SO 2 Ar. Also described is the use of these compounds as pharmaceuticals to treat indications where inhibition of the 5-HT 6 receptor is implicated, such as schizophrenia.

  本文描述了具有对5-HT6受体亲和力的化合物，其具有通式I：其中：R表示式II或式III的基团；A、B、D或E中的一个是N原子，其余为CH基团；R1选自SO2Ar、C（O）Ar、CH2Ar和Ar组成的群；R2、R3和R4独立地选自H和烷基组成的群；-----表示单键或双键，但环中只有一个双键；n为1-3的整数；Z选自C、CH和N组成的群，但当-----为双键时，Z为C，当-----为单键时，Z选自CH和N；Ar是可选取代的芳基基团；但当R是式II的基团时，R1为SO2Ar。还描述了将这些化合物用作药物治疗5-HT6受体抑制相关的疾病，例如精神分裂症。
• Azaindoles Having Serotonin Receptor Affinity
  申请人：Edwards Louise

  公开号：US20080004307A1

  公开（公告）日：2008-01-03

  Described herein are compounds with affinity for the 5-HT 6 receptor, which have the general formula I: wherein A, B, D, E, R 1 to R 3 and n are described herein. Also described is the use of these compounds as pharmaceuticals to treat indications where inhibition of the 5-HT 6 receptor is implicated, such as schizophrenia.

  本文描述了具有亲和力的化合物5-HT6受体，其通式为I:其中A、B、D、E、R1至R3和n如本文所述。还描述了这些化合物作为药物治疗5-HT6受体抑制涉及的症状（如精神分裂症）的用途。
• AZAINDOLES HAVING SEROTONIN RECEPTOR AFFINITY
  申请人：Edwards Louise

  公开号：US20120302596A1

  公开（公告）日：2012-11-29

  Described herein are compounds with affinity for the 5-HT 6 receptor, which have the general formula I: wherein A, B, D, E, R 1 to R 3 and n are described herein. Also described is the use of these compounds as pharmaceuticals to treat indications where inhibition of the 5-HT 6 receptor is implicated, such as schizophrenia.

  本文介绍了具有亲和力的化合物，其与5-HT6受体具有亲和力，其通式为I：其中A、B、D、E、R1至R3和n的描述如本文所述。还描述了这些化合物作为药物用于治疗抑制5-HT6受体有所涉及的适应症，例如精神分裂症。
• US6191141B1
  申请人：——

  公开号：US6191141B1

  公开（公告）日：2001-02-20